Clinical Trials Directory

Trials / Completed

CompletedNCT00797589

Effect of Prime Solution on Fluid Balance After Open Heart Surgery

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
35 (actual)
Sponsor
University of Helsinki · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The use of Tetraspan® as prime solution can reduce fluid extravasation after perfusion versus Ringer acetate. Plasma-adapted HES-solutions produce also less acidosis.

Detailed description

Fifty patients scheduled for elective primary and single cardiac surgery include in this prospective study. Patients with preoperative coagulation disorders, or renal or hepatic failure, are excluded. Before admission to the operation theatre, the patients allocate in random order to receive one of the following solutions during the extracorporeal circulation: 1. Ringer-acetate solution 2. 6% HES solution (Tetraspan®) During the 1 postoperative day we register hemodynamic changes, fluid balance, fluid extravasation, plasma ion concentration, modified thromboelastography, and kidney function.

Conditions

Interventions

TypeNameDescription
DRUGHES20ml/kg as prime fluid
DRUGRinger lactate

Timeline

Start date
2009-01-01
Primary completion
2012-09-01
Completion
2012-09-01
First posted
2008-11-25
Last updated
2015-08-25

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT00797589. Inclusion in this directory is not an endorsement.